biosimilars

Biosimilars in the UK: where are we now and where does the NHS want to go?

https://pharmaphorum.com/views-analysis-market-access/biosimilars-in-the-uk/

https://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/

Four Key Reasons to Attend SMi’s 2019 Biosimilars Conference

https://pharmaphorum.com/partner-content/four-key-reasons-to-attend-smis-2019-biosimilars-conference/

Three years after approval, court blocks US launch of Enbrel biosimilar

https://pharmaphorum.com/news/three-years-after-approval-court-blocks-us-launch-of-enbrel-biosimilar/

Roche under pressure in US as Amgen/Allergan launch US cancer biosimilars

https://pharmaphorum.com/news/roche-under-pressure-in-us-as-amgen-allergan-launch-us-cancer-biosimilars/

10 Key Reasons to attend SMi’s 10th Annual Biosimilars Conference

https://pharmaphorum.com/partner-content/10-key-reasons-to-attend-smis-10th-annual-biosimilars-conference/

Drug Delivery & Formulation Summit 2019

https://pharmaphorum.com/events/drug-delivery-formulation-summit-2019/

Exclusive Interview with ASBM Released Ahead of Upcoming Biosimilars Conference

https://pharmaphorum.com/partner-content/exclusive-interview-with-asbm-released-ahead-of-upcoming-biosimilars-conference/

Optimising market access for biosimilars

https://pharmaphorum.com/views-analysis-market-access/optimising-market-access-for-biosimilars/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search